Epidemiological study for hospitalized patients with community-acquired, health-care-associated, hospital-acquired, and ventilator-associated pneumonia in Japan: a prospective multicenter follow-up study (CJLSG 0911)

Epidemiological study for hospitalized patients with community-acquired, health-care-associated, hospital-acquired, and ventilator-associated pneumonia in Japan: a prospective multicenter follow-up study (CJLSG 0911) - Epidemiological study for hospitalized patients with CAP, HCAP, HAP, and VAP in Japan (CJLSG 0911)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003306

Enrollment

1200

Registered

2010-03-09

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

community-acquired (CAP), health-care-associated (HCAP), hospital-acquired (HAP), and ventilator-associated pneumonia (VAP)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The presence of a new infiltrate on a chest X-ray, or a computed tomography scan, plus at least 2 of the following criteria: 1) cough or purulent sputum, 2) pleuritic chest pain, 3) dyspnea, 4) fever or hypothermia (temperature >= 38 degrees or < 35 degrees), 5) white blood cell count >= 10,000 /mm3 or < 4,000 /mm3, and 6) hypoxemia (SpO2 < 90% or PaO2 < 60 Torr) or decline in oxygenation

Exclusion criteria

Exclusion criteria: 1) Patients who do not receive initial empirical antibiotic treatment 2) Patients with obstructive pneumonia 3) Pneumonia occurred in other hospitals and patients who were transferred from their hospitals with a tendency to improve 4) Patients whose pneumonia recurred within 3 days after the last day of antibiotic treatment of a preceding pneumonia episode 5) Patients who receive the treatment in an outpatient clinic 6) Patients who are less than 20 years old

Design outcomes

Primary

Measure	Time frame
1) 30-day mortality and in-hospital mortality 2) Identified pathogens and drug resistance 3) Early and late treatment failure 4) Appropriateness of antibiotic treatment 5) Outcomes and their clinical prediction rules for patients with each category of pneumonia (CAP, HCAP, HAP, and VAP) 6) Adherence to practice guidelines in initial empirical antibiotic treatment for patients with each category of pneumonia (CAP, HCAP, HAP, and VAP)	—

Measure

Time frame

1) 30-day mortality and in-hospital mortality 2) Identified pathogens and drug resistance 3) Early and late treatment failure 4) Appropriateness of antibiotic treatment 5) Outcomes and their clinical prediction rules for patients with each category of pneumonia (CAP, HCAP, HAP, and VAP) 6) Adherence to practice guidelines in initial empirical antibiotic treatment for patients with each category of pneumonia (CAP, HCAP, HAP, and VAP)

—

Countries

Japan

Contacts

Public ContactYuichiro Shindo

Nagoya University Graduate School of Medicine Respiratory Medicine

yshindo@med.nagoya-u.ac.jp052-744-2167

Outcome results